INTRA CELLULAR THERAPIES INC's ticker is ITCI and the CUSIP is 46116X101. A total of 290 filers reported holding INTRA CELLULAR THERAPIES INC in Q3 2023. The put-call ratio across all filers is 1.03 and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $16,547,583 | +48.0% | 317,856 | +79.7% | 5.57% | +63.7% |
Q2 2023 | $11,182,605 | -19.9% | 176,856 | -31.4% | 3.40% | -12.6% |
Q1 2023 | $13,957,745 | +19.0% | 257,856 | +16.2% | 3.89% | +7.5% |
Q4 2022 | $11,733,964 | +13.9% | 221,856 | 0.0% | 3.62% | +9.7% |
Q3 2022 | $10,303,000 | -83.7% | 221,856 | +6057.5% | 3.30% | +401.4% |
Q2 2022 | $63,156,000 | +201.7% | 3,603 | -92.9% | 0.66% | -86.0% |
Q1 2022 | $20,930,000 | +253.3% | 50,956 | -55.1% | 4.72% | +257.6% |
Q4 2021 | $5,924,000 | +100.3% | 113,456 | +42.8% | 1.32% | +85.1% |
Q3 2021 | $2,957,000 | -8.8% | 79,456 | 0.0% | 0.71% | -16.7% |
Q2 2021 | $3,243,000 | +20.1% | 79,456 | 0.0% | 0.86% | +19.9% |
Q1 2021 | $2,700,000 | +6.8% | 79,456 | 0.0% | 0.71% | +3.5% |
Q4 2020 | $2,527,000 | +296.7% | 79,456 | +220.4% | 0.69% | +235.0% |
Q3 2020 | $637,000 | +10.0% | 24,800 | +7.8% | 0.21% | +7.3% |
Q2 2020 | $579,000 | +64.5% | 23,000 | 0.0% | 0.19% | +20.0% |
Q1 2020 | $352,000 | – | 23,000 | – | 0.16% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Ally Bridge Group (NY) LLC | 175,000 | $9,115,750 | 10.70% |
INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 317,856 | $16,547,583 | 5.57% |
Deep Track Capital, LP | 2,600,000 | $135,434,000 | 5.23% |
SUVRETTA CAPITAL MANAGEMENT, LLC | 1,369,849 | $71,355,434 | 3.86% |
SILVERARC CAPITAL MANAGEMENT, LLC | 208,730 | $10,872,746 | 3.30% |
DCF Advisers, LLC | 107,157 | $5,581,808 | 3.04% |
Bellevue Group AG | 3,170,250 | $165,138,323 | 2.66% |
Vahanian & Associates Financial Planning Inc. | 15,217 | $792,654 | 2.55% |
Iron Triangle Partners LP | 330,549 | $17,218,297 | 2.52% |
TANG CAPITAL MANAGEMENT LLC | 300,000 | $15,627,000 | 2.20% |